|
| Home : Coave Therapeutics and Théa Open Innovation sign exclusive licensing, co-development and commercialization agreement for Europe for CTx-PDE6b, a novel gene therapy candidate in retinitis pigmentosa |
|
Sep 16
2021 |
Coave Therapeutics and Théa Open Innovation sign exclusive licensing, co-development and commercialization agreement for Europe for CTx-PDE6b, a novel gene therapy candidate in retinitis pigmentosa |
|
PARIS, Sept. 16, 2021 /PRNewswire/ -- Coave Therapeutics ('Coave'), a clinical-stage biotechnology company focused on developing life-changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases, has entered into an exclusive licensing, co-development and... |
|
|
|
| Source:https://www.prnewswire.com:443/news-releases/coave-therapeutics-and-thea-open-innovation-sign-exclusive-licensing-co-development-and-commercialization-agreement-for-europe-for-ctx-pde6b-a-novel-gene-therapy-candidate-in-retinitis-pigmentosa-301377909.html |
| |
|
Related News
|
» Asetek Unveils Premium Performance Invicta Sim Racing Pedals
» Avista Capital Partners and Nordic Capital to sell Acino, a leader in advanced drug delivery technologies, to ADQ
|
|
|
